Trial design
USUAL INTERSTITIAL PNEUMONIA
The INBUILD trial (NCT02999178) was a randomised, double-blind, placebo-controlled trial conducted in 15 countries [Patients were randomised to receive nintedanib 150 mg twice daily (bid) or placebo, stratified by fibrotic pattern on HRCT (usual interstitial pneumonia [UIP]-like fibrotic pattern or other fibrotic patterns [described in 